{
    "clinical_study": {
        "@rank": "36860", 
        "arm_group": {
            "arm_group_label": "ALN-TTR02", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and tolerability of long-term dosing\n      with ALN-TTR02 in patients with transthyretin (TTR) mediated amyloidosis (ATTR)."
        }, 
        "brief_title": "The Study of an Investigational Drug, ALN-TTR02, for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02", 
        "completion_date": {
            "#text": "February 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "TTR-mediated Amyloidosis", 
        "condition_browse": {
            "mesh_term": "Amyloidosis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Previously received and tolerated ALN-TTR02 in Study ALN-TTR02-002.\n\n          -  Adequate Karnofsky performance status, liver function, and renal function.\n\n        Exclusion Criteria:\n\n          -  Pregnant or nursing.\n\n          -  Has had a liver transplant.\n\n          -  Has a New York Heart Association heart failure classification >2.\n\n          -  Has unstable angina.\n\n          -  Has uncontrolled clinically significant cardiac arrhythmia."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "28", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01961921", 
            "org_study_id": "ALN-TTR02-003", 
            "secondary_id": "2013-001644-65"
        }, 
        "intervention": {
            "arm_group_label": "ALN-TTR02", 
            "intervention_name": "ALN-TTR02 administered by intravenous (IV) infusion", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "RNAi therapeutic", 
        "lastchanged_date": "April 22, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts"
                    }, 
                    "name": "Clinical Trial Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rio de Janeiro", 
                        "country": "Brazil"
                    }, 
                    "name": "Clinical Trial Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Le Kremlin-bicetre", 
                        "country": "France"
                    }, 
                    "name": "Clinical Trial Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Marseille Cedex", 
                        "country": "France"
                    }, 
                    "name": "Clinical Trial Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Munster", 
                        "country": "Germany"
                    }, 
                    "name": "Clinical Trial Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lisbon", 
                        "country": "Portugal"
                    }, 
                    "name": "Clinical Trial Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Porto", 
                        "country": "Portugal"
                    }, 
                    "name": "Clinical Trial Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Majorca", 
                        "country": "Spain"
                    }, 
                    "name": "Clinical Trial Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ume\u00e5", 
                        "country": "Sweden"
                    }, 
                    "name": "Clinical Trial Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Brazil", 
                "France", 
                "Germany", 
                "Portugal", 
                "Spain", 
                "Sweden"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Safety, Clinical Activity, and Pharmacokinetics of ALN-TTR02 in Patients With Familial Amyloidotic Polyneuropathy Who Have Previously Received ALN-TTR02", 
        "overall_contact": {
            "last_name": "Contact: Alnylam Clinical Trials Hotline. Call for Complete Site List.", 
            "phone": "617-575-7400 or 1-866-330-0326"
        }, 
        "overall_official": {
            "affiliation": "Alnylam Pharmaceuticals", 
            "last_name": "Jared Gollob, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Portugal: National Pharmacy and Medicines Institute", 
                "Sweden: Medical Products Agency", 
                "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "United States: Food and Drug Administration", 
                "Brazil: National Health Surveillance Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Safety and tolerability of long-term dosing with ALN-TTR02 in ATTR patients", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 56 days post last dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01961921"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Assessment of changes from baseline in serum TTR lowering associated with long-term dosing of ALN-TTR02", 
                "safety_issue": "No", 
                "time_frame": "Up to 56 days post last dose"
            }, 
            {
                "measure": "Assessment of changes from baseline in neurologic impairment associated with long-term dosing of ALN-TTR02", 
                "safety_issue": "No", 
                "time_frame": "Up to 56 days post last dose"
            }, 
            {
                "measure": "Assessment of changes from baseline in quality of life and disability associated with long-term dosing of ALN-TTR02", 
                "safety_issue": "No", 
                "time_frame": "Up to 56 days post last dose"
            }, 
            {
                "measure": "Assessment of changes from baseline in motor function associated with long-term dosing of ALN-TTR02", 
                "safety_issue": "No", 
                "time_frame": "Up to 56 days post last dose"
            }, 
            {
                "measure": "Assessment of changes from baseline in nutritional status associated with long-term dosing of ALN-TTR02", 
                "safety_issue": "No", 
                "time_frame": "Up to 56 days post last dose"
            }
        ], 
        "source": "Alnylam Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Alnylam Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}